{
  "pmcid": "12506219",
  "sha256": "9cbb3d9f31fa5e39cfd6cb1db44655bf11c09ee69b8e89e46b8f54dcf237d882",
  "timestamp_utc": "2025-11-09T23:42:36.329863+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 10.886633622470058,
    "reading_ease": 34.75604984166324,
    "word_count": 269
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Prophylactic Fibrinogen Administration in Paediatric Scoliosis Surgery"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "This two-arm, single-centre, randomised, double-blind trial"
      },
      "Participants": {
        "score": 2,
        "evidence": "Thirty-two children undergoing elective scoliosis surgery were randomised"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomised 1:1 to receive either standard blood and coagulation management or a single prophylactic dose of fibrinogen concentrate"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study assesses the safety and feasibility of prophylactic fibrinogen administration in paediatric scoliosis surgery."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was safety, assessed by adverse events (AEs) and serious adverse events (SAEs) during the hospital stay."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated with allocation concealment via a web-based system."
      },
      "Blinding": {
        "score": 3,
        "evidence": "Blinding included patients, clinicians, and outcome assessors."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "Between June 2022 and June 2023, 32 participants were randomised, with 16 in each group."
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "All were analysed using an intention-to-treat approach."
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "Blood loss did not significantly differ between the fibrinogen (1021.88 mL, SD 473.63) and standard (859.38 mL, SD 713.03) groups (p=0.1677)."
      },
      "Harms": {
        "score": 1,
        "evidence": "In the fibrinogen group, 101 AEs across 19 types were observed, while the standard group had 95 AEs across 21 types (p>0.9999)."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: ClinicalTrials.gov NCT05391412."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 23,
    "max_score": 25
  }
}